{"contentid": 488746, "importid": NaN, "name": "UK competition watchdog weighs in on Alexion purchase", "introduction": "AstraZeneca\u00e2\u0080\u0099s planned $39 billion buy of American rare disease specialist Alexion Pharmaceuticals hit a speed bump on Tuesday, after the UK\u00e2\u0080\u0099s antitrust body launched a review of the deal.", "content": "<p>AstraZeneca&rsquo;s (LSE: AZN) planned $39 billion buy of American rare disease specialist Alexion Pharmaceuticals (Nasdaq: ALXN) hit a speed bump on Tuesday, after the UK&rsquo;s antitrust body launched a review of the deal.</p>\n<p>The Competition and Markets Authority (CMA) said that relevant parties had until June 3 to submit input on the process, and that it would decide by July 21 whether to instigate a more thorough investigation.</p>\n<p>In a statement, AstraZeneca described the initiation of the formal review as &ldquo;another important step towards closing of the proposed acquisition.&rdquo;</p>\n<p>The acquisition remains expected to close in the third quarter of 2021, subject to receipt of additional global regulatory clearances.</p>\n<h2>High-value deal</h2>\n<p>Alexion is a leader in complement biology, and AstraZeneca sees value in enhancing its presence in immunology, combining the firm&rsquo;s novel science with its own expertise in precision medicines.</p>\n<p>Rare diseases is also a high-growth therapy area with a high level of unmet medical need. With over 7,000 rare diseases currently known about, just 5% currently have FDA-approved treatments.</p>\n<p>The acquisition, which would add a portfolio of five approved therapies as well as a pipeline of more than twice that number of candidates, has already been approved by the US Federal Trade Commission (FTC).</p>\n<p>Regulators in the EU and in Japan are yet to deliver their verdict, although shareholders of both companies have voted overwhelmingly in favor of the proposal.</p>", "date": "2021-05-26 15:22:00", "meta_title": NaN, "meta_keywords": NaN, "meta_description": NaN, "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-26 12:29:43", "updated": "2021-05-26 15:37:15", "access": NaN, "url": "https://www.thepharmaletter.com/article/uk-competition-watchdog-weighs-in-on-alexion-purchase", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "astrazeneca_big.jpg", "image2id": "astrazeneca_small-1.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Immunologicals, Oncology", "topic_tag": "Companies, mergers and acquisitions, Deals, Government Affairs, Regulation", "geography_tag": "UK, USA", "company_tag": "Alexion Pharmaceuticals, AstraZeneca", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-26 15:22:00"}